REQUEST A DEMO
Total
USD $0.00
Search more companies

Eli Lilly (Malaysia) Sdn. Bhd. (Malaysia)

Main Activities: Pharmacies and Drug Stores | Veterinary Services
Full name: Eli Lilly (Malaysia) Sdn. Bhd. Profile Updated: February 05, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2022 Available in: English Download a sample report

Eli Lilly and Company is a pharmaceutical company specializing in insulin therapy, diabetes treatment, and the development of molecular imaging compounds and obesity treatments. The company focuses on ensuring equitable and affordable access to their medicines and patient safety.

Headquarters
Level 16, The Ascent, Paradigm, No. 1, Jalan Ss7/26A, Kelana Jaya
Petaling Jaya; Selangor; Postal Code: 47301

Contact Details: Purchase the Eli Lilly (Malaysia) Sdn. Bhd. report to view the information.

Website: http://www.lilly.com/

Basic Information
Outstanding Shares:
Purchase the Eli Lilly (Malaysia) Sdn. Bhd. report to view the information.
Registered Capital:
Purchase the Eli Lilly (Malaysia) Sdn. Bhd. report to view the information.
Financial Auditors:
Purchase the Eli Lilly (Malaysia) Sdn. Bhd. report to view the information.
Incorporation Date:
June 13, 1979
Key Executives
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Purchase this report to view the information.
Secretary
Purchase this report to view the information.
Secretary
Ownership Details
Purchase this report to view the information.
100%
Company Performance
Financial values in the chart are available after Eli Lilly (Malaysia) Sdn. Bhd. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency MYR. Absolute financial data is included in the purchased report.
Net sales revenue
-78.15%
Total operating revenue
-78.15%
Operating profit (EBIT)
-70.31%
EBITDA
-70.13%
Net Profit (Loss) for the Period
N/A
Total assets
4.98%
Total equity
1.75%
Operating Profit Margin (ROS)
2.16%
Net Profit Margin
N/A
Return on Equity (ROE)
N/A
Quick Ratio
-0.58%
Cash Ratio
0.4%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?